Impact of Lymphadenectomy on Survival of Patients with Serous Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A French National Multicenter Study (FRANCOGYN).
Fiche publication
Date publication
juillet 2020
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BALDAUF Jean-Jacques, Pr COUTANT Charles, Pr VELTEN Michel, Dr DEMARCHI Martin, Dr GANTZER Justine
Tous les auteurs :
Bund V, Lecointre L, Velten M, Ouldamer L, Bendifallah S, Koskas M, Bolze PA, Collinet P, Canlorbe G, Touboul C, Huchon C, Coutant C, Faller E, Boisramé T, Gantzer J, Demarchi M, Baldauf JJ, Ballester M, Lavoué V, Akladios C
Lien Pubmed
Résumé
The population of interest to this study comprised individuals with advanced-stage ovarian carcinoma who were exposed to neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS). Those who had not received systematic lymphadenectomy (SL; Group 1) were compared to those who had received SL (Group 2). Outcome measures included progression-free survival (PFS), overall survival (OS), and surgical complications.
Mots clés
neoadjuvant chemotherapy, ovarian carcinoma, systematic lymphadenectomy
Référence
J Clin Med. 2020 Jul 29;9(8):